logo
logo
BCRX stock ticker logo

BioCryst Pharmaceuticals, Inc.

NASDAQ•BCRX
CEO: Mr. Jon P. Stonehouse
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1994-03-04
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Contact Information
4505 Emperor Boulevard, Suite 200, Durham, NC, 27703, United States
919-859-1302
www.biocryst.com
Market Cap
$1.93B
P/E (TTM)
7.3
16
Dividend Yield
--
52W High
$11.31
52W Low
$6.00
52W Range
60%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$406.56M+0.00%
4-Quarter Trend

EPS

$1.17+0.00%
4-Quarter Trend

FCF

$275.23M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Surge 2025 Total revenues reached $874.8M, up $424.1M, driven by $243.3M license revenue from European sale.
Return to Net Income Net income reached $263.9M for 2025, significantly reversing prior year net loss of $(88.9M).
Strong Operating Cash Flow Operating cash flow provided $347.4M cash, a major improvement from $(52.0M) used in 2024.
US ORLADEYO Sales Growth US ORLADEYO product sales grew to $548.8M in 2025, reflecting strong patient demand and price increases.

Risk Factors

ORLADEYO Patent Litigation Patent infringement lawsuit filed by Annora challenges four ORLADEYO patents expiring in 2039; outcome uncertain.
Sustained Profitability Uncertainty Sustained profitability remains uncertain; company may need to raise additional capital or obtain future financing when required.
Third-Party Distribution Reliance Reliance on single specialty pharmacy for US distribution creates concentration risk impacting ORLADEYO commercial revenue.
Astria Merger Integration Risk Integrating Astria business acquired in early 2026 may prove difficult, costly, or fail to realize anticipated synergies.

Outlook

Advancing Navenibart Phase 3 Advancing Navenibart (STAR-0215) through Phase 3 clinical development; goal is best-in-class injectable HAE therapy.
Pediatric ORLADEYO Expansion FDA approved oral pellet ORLADEYO for pediatric HAE (age 2 to <12) in December 2025; expanding market.
Seeking Avoralstat Strategic Partner Planning to seek strategic partner for Avoralstat development beyond Phase 1 for Diabetic Macular Edema indication.
BCX17725 Data Expected 2026 Expecting clinical trial data for BCX17725 (Netherton syndrome) in up to 12 patients by end of 2026.

Peer Comparison

Revenue (TTM)

BCRX stock ticker logoBCRX
$874.84M
+94.1%
ARDX stock ticker logoARDX
$427.68M
+18.2%
XERS stock ticker logoXERS
$291.85M
+43.7%

Gross Margin (Latest Quarter)

NBTX stock ticker logoNBTX
100.0%
+0.0pp
ATAI stock ticker logoATAI
100.0%
+0.0pp
WVE stock ticker logoWVE
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SYRE$4.19B-154.8-29.4%0.0%
ZYME$1.98B-24.7-26.0%5.3%
TRVI$1.97B-47.2-25.5%0.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
40.8%
Strong Growth
4Q Net Income CAGR
1873.2%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:$0.07
|
Revenue:$151.66M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data